Form 4: Bone Biologics Director Robert Gagnon Reports Significant New Stock Option Grant

Bone Biologics Corp. Director Robert E. Gagnon has reported the acquisition of 62,894 non-employee stock options at an exercise price of $0.88, granted on June 4, 2025, under the company's 2015 Equity Incentive Plan.

Summary

• Robert E. Gagnon, a Director of Bone Biologics Corp. (BBLG), filed a Form 4 reporting changes in his beneficial ownership of derivative securities.
• On June 4, 2025, Mr. Gagnon was granted 62,894 non-employee stock options under the Bone Biologics Corporation 2015 Equity Incentive Plan.
• These newly granted options have an exercise price of $0.88 per share and are set to expire on June 4, 2035.
• The 62,894 options will vest in four equal quarterly installments.
• Mr. Gagnon also holds previously granted non-employee stock options, including 30,713 options at an exercise price of $1.73 (granted on September 17, 2024, vesting quarterly) and a total of 8,015 options (9 + 8,006) at an exercise price of $4.68, which are fully exercisable as of the report date.
• Following these reported transactions, Mr. Gagnon beneficially owns a total of 101,622 derivative securities (stock options) in Bone Biologics Corp.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, indicating potential confidence in future company performance, despite the inherent dilution risk.

Positives

• The grant of stock options to a director aligns management's financial interests with those of shareholders, as the options' value is tied to the company's stock price performance.
• The relatively low exercise price of the newly granted options ($0.88) may incentivize the director to contribute to future stock price appreciation.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if and when these options are exercised, increasing the total number of outstanding shares.

Risks

• Potential future dilution risk for existing shareholders if the granted options are exercised, which would increase the number of outstanding shares.
• The value of the stock options is inherently dependent on the future performance of Bone Biologics Corp.'s stock price, which is subject to various market and operational risks.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This filing is a standard insider transaction report (Form 4) and does not provide broader industry context. It reflects a compensation event for a director within the biotechnology or medical device sector, specifically related to bone regeneration.

Corporate Governance

Related Party Transactions

• Grant of 62,894 non-employee stock options to Robert E. Gagnon, a Director of Bone Biologics Corp., under the company's 2015 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of director's incentives with shareholder value creation.
• Management/Directors: Provides a significant component of compensation tied to the company's stock performance, incentivizing long-term growth.

Key Dates

Keywords

Bone Biologics, BBLG, Form 4, Insider Transaction, Stock Options, Equity Incentive Plan, Director Compensation, Beneficial Ownership, SEC Filing